Vertex Pharmaceuticals (NASDAQ: VRTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-28 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.490 | 3.520 | 0.0300 | ||||
REV | 2.080B | 2.097B | 17.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vertex Pharmaceuticals (NASDAQ: VRTX) through any online brokerage.
Other companies in Vertex Pharmaceuticals’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Vertex Pharmaceuticals (NASDAQ: VRTX) was reported by Argus Research on Monday, June 13, 2022. The analyst firm set a price target for 280.00 expecting VRTX to fall to within 12 months (a possible -4.29% downside). 23 analyst firms have reported ratings in the last year.
The stock price for Vertex Pharmaceuticals (NASDAQ: VRTX) is $292.55 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vertex Pharmaceuticals.
Vertex Pharmaceuticals’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for Vertex Pharmaceuticals.
Vertex Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.